Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crovalimab in Sickle Cell Disease
NCT05075824Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2022
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of crovalimab in sickle cell disease (SCD), sponsored by Roche. Started Mar 2022; status: completed.
02
Drugs
crovalimab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05075824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05075824.